ArticleFrontiers in oncology2023
Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
Fei Qu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.